1. Clinical Overview
Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. At a 10mcg dose, it is primarily used for the management of moderate to severe acute pain. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist, offering a unique pharmacological profile with a ceiling effect on respiratory depression, making it potentially safer than full agonists in certain contexts. In India, it is a critical component of pain management protocols, especially in post-operative and cancer pain scenarios.
| Onset | Duration | Bioavailability |
|---|---|---|
| Sublingual: 30-60 minutes; Parenteral: 15-30 minutes. | Approximately 6-8 hours for analgesia. | Sublingual: 30-55%; Intranasal: ~48%; Parenteral: 100%. |
2. Mechanism of Action
Buprenorphine binds with high affinity to central nervous system opioid receptors, primarily mu-opioid receptors. It acts as a partial agonist at the mu-receptor, producing sufficient agonist effect for analgesia but with a ceiling (plateau) on effects like respiratory depression. It acts as an antagonist or weak partial agonist at the kappa-opioid receptor, which may contribute to a lower incidence of dysphoria and psychotomimetic effects compared to some other opioids.
3. Indications & Uses
- Management of moderate to severe acute pain (e.g., post-operative pain, trauma)
- Management of chronic pain (e.g., cancer pain, neuropathic pain) as part of a comprehensive plan
4. Dosage & Administration
Adult Dosage: For acute pain (sublingual): Initial dose 200-400 mcg (as a single dose or divided). The 10mcg strength is not typically used alone for dosing but is available for precise titration. Dosing is highly individualized. A common regimen may involve starting with higher strengths and using 10mcg tablets for fine adjustment. Maximum single dose for acute pain is typically 600-800 mcg. Doses above 1mg may not provide significantly greater analgesia due to ceiling effect.
Administration: Sublingual tablets: Place under the tongue and allow to dissolve completely. Do not chew, swallow, or crush. Avoid eating or drinking until the tablet is fully dissolved to ensure proper absorption. For post-operative pain, doses are usually administered every 6-8 hours as needed.
5. Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Constipation
- Dizziness
- Vertigo
- Headache
- Sedation/drowsiness
- Sweating
- Dry mouth
- Miosis (pinpoint pupils)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other CNS Depressants (Benzodiazepines, Alcohol, Barbiturates, Sedatives/Hypnotics) | Additive CNS depression, profound sedation, respiratory depression, coma, death. | Major |
| CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir, Grapefruit juice) | Increased buprenorphine plasma levels, increased risk of toxicity. | Moderate |
| CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased buprenorphine plasma levels, reduced efficacy, potential withdrawal. | Moderate |
| MAO Inhibitors (Phenelzine, Tranylcypromine) | Potentiation of opioid effects, risk of serotonin syndrome, severe CNS reactions. | Major |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol, Triptans) | Increased risk of serotonin syndrome. | Moderate |
| Anticholinergics | Increased risk of urinary retention and severe constipation. | Moderate |
| Full Opioid Agonists (Morphine, Fentanyl, Oxycodone) | Buprenorphine may block the effects of full agonists or precipitate withdrawal in dependent patients. | Major |
| Muscle Relaxants | Enhanced neuromuscular blocking action, increased respiratory depression. | Moderate |
7. Patient Counselling
- DO take exactly as prescribed. Do not increase dose or frequency without consulting doctor.
- DO place the sublingual tablet under your tongue and let it dissolve completely. Do not chew or swallow it.
- DO inform all your healthcare providers (doctors, dentists) that you are taking this medicine.
- DONT consume alcohol or take other sedative medicines (sleeping pills, anxiety pills) without doctor's approval.
- DONT drive, operate heavy machinery, or perform hazardous tasks until you know how the medicine affects you.
- DONT stop the medicine suddenly if taken for a long time; taper off under medical supervision to avoid withdrawal.
8. Toxicology & Storage
Overdose: Pinpoint pupils, respiratory depression (which may progress to apnea), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, hypotension, circulatory collapse, cardiac arrest, death.
Storage: Store at controlled room temperature, 15°C to 30°C. Protect from moisture and light. Keep in the original blister pack or container. Keep out of reach of children and others for whom it is not prescribed. Dispose of unused tablets safely as per pharmacy guidelines; do not flush down toilet or throw in household trash.